Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda […]readmore
Tags : License Agreement
Shots: Bio-Thera to receive $20M up front and $130M as development and commercial milestones and will be responsible for the development, manufacturing, and supply of BAT2206 Hikma get exclusive rights […]readmore
Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights of abicipar globally Molecular Partners […]readmore
Shots: Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s ADC technologies for one therapeutic […]readmore
Shots: Under Dzuveo agreement, AcelRx to receive ~$55M as an up front and commercial milestones in addition to 35% to 45% revenue share on net sales of Dzuveo. AcelRx will […]readmore
Shots: IRLAB to receive ~$363M, including $28M as up front and ~$335M as development, regulatory and commercial milestones along with royalties on WW net sales of mesdopetam Ipsen get the […]readmore
Shots: ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules The collaboration validates the immense clinical and commercial potential of UM171 […]readmore
Shots: InnoCare to receive $125M as up front & is eligible to receive ~ $812.5M as development & commercial milestones, following the achievement of definite milestones along with royalties on […]readmore
Shots: Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the […]readmore
Shots: Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 in licensed countries. Pfizer gets […]readmore